Travis Perkins

  • ISIN: GB00BK9RKT01
  • Land: Großbritannien

Alle Mitteilungen

EQS-Reg 03.12.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 02.12.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 01.12.21 13:17 EQS-Reg: Travis Perkins
Travis Perkins: Total Voting Rights
EQS-Reg 01.12.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 30.11.21 08:44 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 29.11.21 12:36 EQS-Reg: Travis Perkins
Travis Perkins: Directorate Change
EQS-Reg 29.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 26.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 25.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 24.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 23.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 22.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 19.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 18.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 17.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 16.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 12.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 11.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 10.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares
EQS-Reg 09.11.21 08:00 EQS-Reg: Travis Perkins
Travis Perkins: Transaction in Own Shares

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021